Want to join the conversation?
$LVLT 2Q15 Call: Adjusted EBITDA margins expanded to 32.3% in 2Q15, up from 29.4% on a pro forma basis in 2Q14. YoverY CNS revenue grew 5.4% on constant currency basis and 2.9% on an as reported basis. The company generated free cash flow of $102MM.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)